Jefferies Sees Biogen's (BIIB) Aducanumab More Likely Approved Than Not in the Coming Days
Go back to Jefferies Sees Biogen's (BIIB) Aducanumab More Likely Approved Than Not in the Coming Days| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 209.83 -0.82 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $210.65 | 52 Week High | $333.65 | |||
| Open | $210.01 | 52 Week Low | $223.02 | |||
| Day High | $210.79 | P/E | 26.87 | |||
| Day Low | $208.22 | EPS | $7.81 | |||
| Volume | 554,817 | |||||
